James Larkin

5 ta ish

Royal Marsden NHS Foundation Trust

1. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

   James Larkin, Vanna Chiarion‐Sileni, René González +28

   MaqolaOAOchiq kirish20153 iqtibos

   ABIABI:AkademIndex/2026.other.170114

2. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

   Marco Gerlinger, Andrew J. Rowan, Stuart Horswell +27

   MaqolaOAOchiq kirish20122 iqtibos

   ABIABI:AkademIndex/2026.other.014404

3. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

   Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González +30

   MaqolaOAOchiq kirish20172 iqtibos

   ABIABI:AkademIndex/2026.other.082822

4. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

   Robert J. Motzer, Bernard Escudier, Ray McDermott +24

   Maqola20152 iqtibos

   ABIABI:AkademIndex/2026.other.679071

5. Immune checkpoint inhibitors in melanoma

   Matteo S. Carlino, James Larkin, Georgina V. Long

   Sharh maqola20212 iqtibos

   ABIABI:AkademIndex/2026.other.801846